NCBP2AS2

Across TCGA pan-cancer cohorts, NCBP2AS2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NCBP2AS2 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher NCBP2AS2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated NCBP2AS2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where NCBP2AS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	II,III,IV	0.604	0.862	.001	27	view →
PDAC	DFS	Tertile	II,III,IV	0.199	0.433	.035	7	view →
GBM	DFS	Tertile	All	0.611	0.905	<.001	6	view →
HNSC	OS	Median	IV	0.820	0.614	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

NCBP2AS2–CCRCC (OS)

Open the CCRCC breakdown →